Dupixent® (dupilumab) – Expanded indication
March 11, 2019 - Regeneron Pharmaceuticals and Sanofi announced the FDA approval of Dupixent (dupilumab), for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Top